Increased expression of interleukin-32 in the inflamed ileum of ankylosing spondylitis patients

Rheumatology (United Kingdom)

Volumn 51, Issue 11, 2012, Pages 1966-1972

  Ciccia, Francesco ^a   Rizzo, Aroldo ^b   Accardo palumbo, Antonina ^b   Giardina, AnnaRita ^a   Bombardieri, Michele ^c   Guggino, Giuliana ^a   Taverna, Simona ^a   Leo, Giacomo De ^a   Alessandro, Riccardo ^a   Triolo, Giovanni ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello   (Italy)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Ankylosing spondylitis; Crohn's disease; IL 32; Intestinal inflammation; Paneth cells

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 32; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; FEMALE; HUMAN; HUMAN TISSUE; ILEUM; IMMUNOHISTOCHEMISTRY; INTESTINE EPITHELIUM CELL; MALE; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TISSUE DISTRIBUTION; UPREGULATION;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CROHN DISEASE; EPITHELIAL CELLS; FEMALE; HCT116 CELLS; HUMANS; ILEITIS; ILEUM; IMMUNITY, INNATE; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-1BETA; INTERLEUKINS; MACROPHAGES; MALE; MIDDLE AGED; RNA, MESSENGER; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84867769342     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes170     Document Type: Article

References (22)

1. De Vos M, Mielants H, Cuvelier C, Elewaut A, Veys E. Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology 1996; 110: 1696-703.
2. Ciccia F, Bombardieri M, Principato A et al. Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum 2009; 60: 955-65.
3. Ciccia F, Bombardieri M, Rizzo A et al. Over-expression of paneth cell-derived anti-microbial peptides in the gut of patients with ankylosing spondylitis and subclinical intestinal inflammation. Rheumatology 2010; 49: 2076-83.
4. Ciccia F, Accardo-Palumbo A, Giardina A et al. Expansion of intestinal CD4+CD25(high) Treg cells in patients with ankylosing spondylitis: a putative role for interleukin-10 in preventing intestinal Th17 response. Arthritis Rheum 2010; 62: 3625-34.
5. Joosten LA, Netea MG, Kim SH et al. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci USA 2006; 103: 3298-303.
6. Shioya M, Nishida A, Yagi Y et al. Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease. Clin Exp Immunol 2007; 149: 480-6.
7. Ciccia F, Alessandro R, Rizzo A et al. Expression of interleukin-32 in the inflamed arteries of patients with giant cell arteritis. Arthritis Rheum 2011; 63: 2097-104.
8. Jung MY, Son MH, Kim SH, Cho D, Kim TS. IL-32gamma induces the maturation of dendritic cells with Th1- and Th17-polarizing ability through enhanced IL-12 and IL-6 production. J Immunol 2011; 186: 6848-59.
9. Netea MG, Azam T, Ferwerda G et al. IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism. Proc Natl Acad Sci USA 2005; 102: 16309-14.
10. Strober W, Kitani A, Fuss I, Asano N, Watanabe T. The molecular basis of NOD2 susceptibility mutations in Crohn's disease. Mucosal Immunol 2008; 1(Suppl 1): S5-9.
11. Strober W, Watanabe T. NOD2, an intracellular innate immune sensor involved in host defense and Crohn's disease. Mucosal Immunol 2011; 4: 484-95.
12. Watanabe T, Kitani A, Strober W. NOD2 regulation of Toll-like receptor responses and the pathogenesis of Crohn's disease. Gut 2005; 54: 1515-8.
13. Andoh A, Yagi Y, Shioya M et al. Mucosal cytokine network in inflammatory bowel disease. World J Gastroenterol 2008; 14: 5154-61.
14. Kobayashi KS, Chamaillard M, Ogura Y et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005; 307: 731-4.
15. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-8.
16. Garrett S, Jenkinson T, Kennedy LG et al. A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index. J Rheumatol 1994; 21: 2286-91.
17. Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn's disease activity index. National cooperative Crohn's disease study. Gastroenterology 1976; 70: 439-44.
18. Taverna S, Flugy A, Colomba P et al. Effects of Parietaria judaica pollen extract on human microvascular endothelial cells. Biochem Biophys Res Commun 2008; 372: 644-9.
19. Choi J, Bae S, Hong J et al. Paradoxical effects of constitutive human IL-32{gamma} in transgenic mice during experimental colitis. Proc Natl Acad Sci USA 2010; 107: 21082-6.
20. Fantini MC, Monteleone G, Macdonald TT. New players in the cytokine orchestra of inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 1419-23.
21. Madsen KL, Lewis SA, Tavernini MM, Hibbard J, Fedorak RN. Interleukin 10 prevents cytokine-induced disruption of T84 monolayer barrier integrity and limits chloride secretion. Gastroenterology 1997; 113: 151-9.
22. McHeyzer-Williams M, Okitsu S, Wang N, McHeyzer-Williams L. Molecular programming of B cell memory. Nat Rev Immunol 2012; 12: 24-34.